AstraZeneca PLC (LON:AZN) Receives Average Rating of “Moderate Buy” from Brokerages

AstraZeneca PLC (LON:AZN) has received an average rating of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is GBX 7,935.67 ($98.73).

Several research analysts have recently issued reports on AZN shares. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. Berenberg Bank reaffirmed a “buy” rating and set a GBX 140 ($1.74) target price on shares of AstraZeneca in a report on Monday, January 27th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating and issued a £140 ($174.17) price objective on shares of AstraZeneca in a research note on Friday, November 22nd.

AstraZeneca Trading Down 1.2 %

LON:AZN opened at £111.44 ($138.64) on Thursday. AstraZeneca has a 1 year low of GBX 9,461 ($117.70) and a 1 year high of £133.88 ($166.56). The stock has a market cap of £172.73 billion, a price-to-earnings ratio of 3,537.78, a PEG ratio of 0.86 and a beta of 0.17. The business has a fifty day moving average of £106.90 and a 200-day moving average of £115.17. The company has a debt-to-equity ratio of 84.97, a quick ratio of 0.59 and a current ratio of 0.89.

Insiders Place Their Bets

In related news, insider Tony Mok acquired 1,500 shares of the stock in a transaction dated Tuesday, November 19th. The shares were acquired at an average price of £126.80 ($157.75) per share, with a total value of £190,200 ($236,626.03). Also, insider Pascal Soriot acquired 20,000 shares of the stock in a transaction dated Thursday, November 14th. The shares were bought at an average cost of £102.03 ($126.93) per share, for a total transaction of £2,040,600 ($2,538,691.22). Insiders own 0.04% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.